Brazilian AIDS Group Opposes Patent In India
This article was originally published in PharmAsia News
MUMBAI - Citizen groups in Brazil and India have opposed the grant of a patent to Gilead Sciences' anti-retroviral drug tenofovir
You may also be interested in...
MUMBAI - Multinational pharmaceutical companies eyeing the growing Indian market may find themselves confronting a challenging patent environment during the next few years as public interest groups look to further intensify patent oppositions
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).